Clinical Trials
6
Active:1
Completed:2
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
2 (33.3%)Early Phase 1
1 (16.7%)SGT-53 in Children With Recurrent or Progressive CNS Malignancies
Early Phase 1
Not yet recruiting
- Conditions
- Childhood CNS Tumor
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03554707
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02354547
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02340117
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02340156
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳China Medical University Hospital, Taichung, Taiwan
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasm
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01517464
- Locations
- 🇺🇸
University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found